Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Exacerbation frequency and FEV1 decline of COPD: is it geographic?

Terence A.R. Seemungal, Jadwiga A. Wedzicha
European Respiratory Journal 2014 43: 1220-1222; DOI: 10.1183/09031936.00046014
Terence A.R. Seemungal
1Dept of Clinical Medical Sciences, St Augustine Campus, University of the West Indies, St Augustine, Trinidad and Tobago
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jadwiga A. Wedzicha
2National Heart and Lung Institute, Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: j.wedzicha@imperial.ac.uk
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Chronic obstructive pulmonary disease (COPD) exacerbations are episodes of symptom worsening that have major impacts on a variety of health outcomes, including quality of life, hospital admission and death [1]. Exacerbation reduction is now a key outcome for pharmacological therapies in COPD and, thus, if exacerbation can be prevented how does this affect disease progression and lung function decline?

The issue of the importance of lung function decline in COPD first arose when Fletcher and Peto [2] explored lung function in a cohort of 792 male British postal workers. These subjects were studied over 8 years and it was found that exacerbations were associated with the ratio of forced expiratory volume in 1 s (FEV1) to the cube of the height, although the exacerbation definition was limited at that time. This work was followed in close succession by a study from Utah in which Kanner et al. [3] showed that exacerbation frequency was related to COPD severity, thus implicating exacerbation frequency as a factor in FEV1 decline. However, detecting the relationship proved elusive until the Lung Health Study showed that in smokers and intermittent quitters each additional exacerbation reported to physicians caused a greater annual decline of 7 mL [4]. The following year, the London COPD cohort study reported that in patients with a history of more frequent exacerbations there was an increased rate of decline of 8 mL per year compared with infrequent exacerbators [5]. The relationship between exacerbation frequency and FEV1 decline in COPD has also been seen in the UPLIFT study [6] and another study from Greece [7]. All of these studies were performed on European or North American subjects with COPD.

In diseases other than COPD, an occasional relationship has been reported between exacerbation rates and FEV1 decline. In a study of asthmatics over a period of 11 years, a relationship was seen between exacerbation frequency and FEV1 decline [8]. In a Canadian study, Waters et al. [9] showed that severe cystic fibrosis exacerbations (requiring hospitalisation) were associated with greater FEV1 decline. Although the European Cystic Fibrosis Society study did not report on exacerbations they have reported a link between chronic Pseudomonas aeruginosa infection (a known risk factor for cystic fibrosis exacerbations) and FEV1 decline [10], from which such a relationship may be inferred and this supports the findings of the Canadian study.

In this issue of the European Respiratory Journal, the relationship between exacerbations and lung function decline is addressed in a cohort of 279 Japanese subjects followed over a 5-year period in Hokkaido [11]. The detection rate for exacerbations in this study was 0.78 events per year using a symptom-based definition. The study found no significant relation between exacerbation rate and FEV1 decline. The annual decline in FEV1 in the Hokkaido study was 32 mL·year−1 similar to that found in the London COPD study [5] and somewhat less than that observed in the Lung Health study (∼45 mL·year−1) [4]. Thus, it is unlikely that the lack of a relationship between FEV1 decline and exacerbation rates in the Hokkaido study was due to a milder progression of COPD in subjects from Hokkaido.

There has been much written about definitions of COPD exacerbations and their frequencies; generally the more closely subjects are followed, the higher the exacerbation rates observed. Support for this comes from several studies but we need only consider a few cohort studies of over 100 patients. Monto et al. [12] followed 142 patients by weekly telephone calls and found an exacerbation rate of 2.33 events per year, but Anthonisen et al. [13] followed 173 patients and found a rate of 1.3 events per year relying on 3 monthly patient recall. The London COPD study using monthly visits and daily diary cards found an average rate of 2.9 exacerbations per year [5]. In China, a study of carbocisteine using a diary cards for exacerbation detection and using the Anthonisen definition for an exacerbation, found mean exacerbation rates of 1.01 and 1.35 per year in the two arms of the study that are not much greater than those reported in the Hokkaido Study [14]. However, with close follow-up and daily monitoring Xu et al. [15] have reported, from China, an exacerbation rate of about 2 events per year with ∼50% not reported to physicians. This nonreporting rate of at least 50% for COPD exacerbations was first observed by the London COPD study [16]. The recent SPARK study of inhaled dual bronchodilation in prevention of COPD exacerbations used electronic daily diaries to aid exacerbation detection and the study reported high total exacerbation rates [17].

Despite numerous studies no reproducible differences have been found between reported and unreported exacerbations. One study has reported that the greater the number of unreported exacerbations the worse the quality of life score and the greater the risk of hospital admission [18]. Thus, unreported exacerbations constitute a clear source of health burden in COPD. In the Hokkaido study exacerbations were detected by reply-paid postcards. The response rate for these cards was very high (>99%), but the questions on the postcard appeared only to allow for patient recall of events. Only if an event was suspected was a telephone call made to the patient and this would have occurred well after the event, requiring patient recall of the event. Thus, there was no daily monitoring of exacerbation symptoms in this study and it is, therefore, not surprising that the event rates were so low.

The TORCH study was the first international study to consider COPD exacerbation rates between northern, southern and tropical countries [18]. There was an apparent difference between communities in exacerbation rates and this suggests, along with the Hokkaido study, that there are geographic differences in exacerbation rate. While this may be so the difference may well be much smaller than anticipated when unreported exacerbations are taken into account. It is now time to collect all exacerbation events, whether reported, self-managed or untreated, so that we can recognise the true health burden of exacerbations in COPD patients.

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

  • Received March 10, 2014.
  • Accepted March 10, 2014.
  • ©ERS 2014

References

  1. ↵
    1. Wedzicha JA,
    2. Seemungal TAR
    . COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786–796.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Fletcher EC,
    2. Peto R
    . The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645–1648.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Kanner RE,
    2. Renzetti AD Jr.,
    3. Klauber MR,
    4. et al
    . Variables associated with changes in spirometry in patients with obstructive lung diseases. Am J Med 1979; 67: 44–50.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Kanner RE,
    2. Anthonisen NR,
    3. Connett JE
    . Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 358–364.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Donaldson GC,
    2. Seemungal TAR,
    3. Bhowmik A,
    4. et al
    . Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Halpin DM,
    2. Decramer M,
    3. Celli B,
    4. et al
    . Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 653–661.
    OpenUrlPubMed
  7. ↵
    1. Makris D,
    2. Moschandreas J,
    3. Damianaki A,
    4. et al
    . Exacerbations and lung function decline in COPD: new insights in current and ex-smokers. Respir Med 2007; 101: 1305–1312.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Bai TR,
    2. Vonk JM,
    3. Postma DS,
    4. et al
    . Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007; 30: 452–456.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Waters V,
    2. Stanojevic S,
    3. Atenafu EG,
    4. et al
    . Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012; 40: 61–66.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Kerem E,
    2. Viviani L,
    3. Zolin A,
    4. et al
    . Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of the ECFS Patient Registry. Eur Respir J 2014; 43: 125–133.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Suzuki M,
    2. Makita H,
    3. Ito YM,
    4. et al
    . Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J 2014; 43: 1289–1297.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Monto AS,
    2. Higgins MW,
    3. Ross HW
    . The Tecumseh study of respiratory illness. VIII. Acute infection in chronic respiratory disease and comparison groups. Am Rev Respir Dis 1975; 111: 27–36.
    OpenUrlPubMedWeb of Science
  13. ↵
    1. Anthonisen NR,
    2. Manfreda J,
    3. Warren CP,
    4. et al
    . Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Zheng JP,
    2. Kang J,
    3. Huang SG,
    4. et al
    . Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371: 2013–2018.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Xu W,
    2. Collet J-P,
    3. Shapiro S,
    4. et al
    . Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J 2010; 35: 1022–1030.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Seemungal TA,
    2. Donaldson GC,
    3. Paul EA,
    4. et al
    . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Wedzicha JA,
    2. Decramer M,
    3. Ficker JH,
    4. et al
    . Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199–209.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Wilkinson TMA,
    2. Donaldson GC,
    3. Hurst JR,
    4. et al
    . Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298–1303.
    OpenUrlCrossRefPubMedWeb of Science
    1. Jenkins CR,
    2. Celli B,
    3. Anderson JA,
    4. et al
    . Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J 2012; 39: 38–45.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 43 Issue 5 Table of Contents
European Respiratory Journal: 43 (5)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Exacerbation frequency and FEV1 decline of COPD: is it geographic?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Exacerbation frequency and FEV1 decline of COPD: is it geographic?
Terence A.R. Seemungal, Jadwiga A. Wedzicha
European Respiratory Journal May 2014, 43 (5) 1220-1222; DOI: 10.1183/09031936.00046014

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Exacerbation frequency and FEV1 decline of COPD: is it geographic?
Terence A.R. Seemungal, Jadwiga A. Wedzicha
European Respiratory Journal May 2014, 43 (5) 1220-1222; DOI: 10.1183/09031936.00046014
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Epigenetic association studies at birth and lung function development
  • Are tertiary lymphoid structures necessary for lung defence?
  • Unconventional role for mitochondrial antiviral signalling protein in pulmonary fibrosis
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society